VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP 5 G
VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) : 5 G · DIN 02405822 · STERIMAX INC
Health Canada status: MARKETED
What is VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP?
VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP 5 G contains VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) : 5 G. It is listed in the Health Canada Drug Product Database under DIN 02405822, held by STERIMAX INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 19-Oct-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP used for?
Severe/life-threatening staphylococcal infections (resistant or penicillin-allergic). Oral use for C. difficile pseudomembranous colitis and staphylococcal enterocolitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02405822 |
|---|---|
| Brand name | VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP |
| Generic / active ingredient | VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) : 5 G |
| Manufacturer | STERIMAX INC |
| Strength | 5 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01XA01 VANCOMYCIN |
| AHFS class | 08:12.28.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Oct-2020 |
| Original market date | 2020-10-19 00:00:00 |
How is it administered?
IV: 500 mg q6h or 1 g q12h. Infuse at ≤10 mg/min or over ≥60 min. Oral (colitis only): 125-500 mg q6-8h for 7-10 days. Adjust dose for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Dry powder: 15°C to 25°C. Reconstituted/diluted: 24h at room temp, 72h-96h refrigerated (5°C).
How is it supplied?
500 mg (10/20 mL vials, packs of 10/25); 1 g (20 mL vials, pack of 10); 5 g and 10 g Pharmacy Bulk Packages (100 mL vials).
Contraindications
Known hypersensitivity to the antibiotic.
Warnings and precautions
Rapid infusion may cause hypotension/shock. Ototoxicity (serum >80 mcg/mL). Nephrotoxicity risk. Avoid IM injection (tissue irritation/necrosis). Monitor renal/auditory function.
Is VANCOMYCIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by BAXTER CORPORATION, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP
What can be used instead?
Other Canadian products sharing ATC code J01XA01 VANCOMYCIN. 22 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 1 G | POWDER FOR SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02435721 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02342863 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 10 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02405830 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | DIN 02435713 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02342855 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02394634 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02406543 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02139383 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02533006 |
| VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02543982 |
Who else supplies VANCOMYCIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VANCOMYCIN appears in 172 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for VANCOMYCIN HYDROCHLORIDE FOR INJECTION USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.